HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Plant-Sourced Food Additive Options For Vitamin D2 Expand To Mushroom Powder

Executive Summary

FDA amends food additive regulations with Oakshire’s petition to use agaricus bisporus mushroom powder, produced using UV light treatment, as a source of vitamin D2 in foods and supplements.

You may also be interested in...



Partnership In Israel Cultivates Combining Cannabis And Mushrooms For Supplements

VMS firm Ambrosia-SupHerb partners with cannabis product developer Tikun-Olam to create Israel’s first cannabis and mushroom supplement line.

EU Regulatory Round-Up: EFSA Scientific Opinions On Novel Foods, Vitamin K2 Health Claim

Vitamin D mushroom powder, selenium- and chromium-enriched biomass of y. lipolytica and astaxanthin-based pink coloring are novel foods considered by the European Food Safety Authority's Authority’s Panel on Nutrition, Novel Foods and Food Allergens. The NDA also rejects a health claim for NattoPharma’s vitamin K2 food supplement, MenaQ7.

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel